Originally meant as a marker of inflammation in coronary heart disease (CHD), C reactive protein (CRP) is becoming an important tool in the clinical management of CHD patients. Several studies, and in particular the recent JUPITER trial, confirm its feasibility in intermediate risk patients; furthermore, according to last evidence, CRP could be a target for new therapeutic strategies.